Pediatric devices still have few premarket studies in children

April 15, 2014
Pediatric devices still have few premarket studies in children

(HealthDay)—Most high-risk pediatric devices are approved based on trials that don't involve children under 18 years of age, according to a study published online April 14 in Pediatrics.

Thomas J. Hwang, from Harvard University in Boston, and colleagues identified all high-risk (class III) devices approved through the U.S. Food and Drug Administration's (PMA) or humanitarian device exemption pathways for use in children (between 2008 and 2011). Clinical trial design (randomization, blinding, controls, and types of end points), age distribution of trial participants, and FDA-mandated postmarketing trials were identified.

The researchers found that, over the study period, 22 devices were approved for use in via the PMA pathway and three via the humanitarian device exemption pathway. The majority of devices (88 percent) qualified as pediatric despite minimum approval ages of ≥18 years (the FDA considers aged 18 to 21 years old as pediatric). Nonrandomized (59 percent), open-label (68 percent) studies with surrogate effectiveness end points (77 percent) contributed to most device approvals. Most devices (84 percent) were not studied in any patients younger than 18 years of age. Roughly three-quarters of devices were mandated to have postmarketing studies, although only three required enrollment of .

"Most high-risk pediatric devices are approved on the basis of trials in patients ≥18 years old, with few pediatric patients exposed to the devices before market availability," the authors write.

Explore further: Most high-risk cardiac devices in use today approved as modifications to previously-approved devices

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Most newly approved biologics studied in peds population

January 15, 2013

(HealthDay)—The majority of biologics approved since 1997 include pediatric information in their labeling and have been studied in pediatric trials, according to a review published online Jan. 14 in Pediatrics.

US approves first heart pump for children

December 18, 2011

The US Food and Drug Administration has approved a first mechanical cardiac assist device for children that can help keep patients alive as they await a transplant.

Children continue to be underrepresented in drug trials

July 23, 2012

(HealthDay) -- Even for conditions with a high pediatric disease burden, only a small proportion of clinical drug trials study pediatric patients, according to research published online July 23 in Pediatrics.

Recommended for you


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.